MX2009012486A - Una formulacion liquida para administrar nicotina. - Google Patents

Una formulacion liquida para administrar nicotina.

Info

Publication number
MX2009012486A
MX2009012486A MX2009012486A MX2009012486A MX2009012486A MX 2009012486 A MX2009012486 A MX 2009012486A MX 2009012486 A MX2009012486 A MX 2009012486A MX 2009012486 A MX2009012486 A MX 2009012486A MX 2009012486 A MX2009012486 A MX 2009012486A
Authority
MX
Mexico
Prior art keywords
nicotine
liquid formulation
disease
tobacco
subject
Prior art date
Application number
MX2009012486A
Other languages
English (en)
Inventor
Fredrik Nicklasson
John Hedenstroem
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of MX2009012486A publication Critical patent/MX2009012486A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una formulación líquida farmacéutica para suministrar nicotina en cualquiera de sus formas a un sujeto mediante captación transdérmica, para el tratamiento de dependencia al tabaco o trastornos similares, caracterizada además porque la formulación mencionada es una loción corporal medicinal, un bálsamo corporal medicinal o un gel corporal medicinal; también se contemplan un método para suministrar nicotina, un método para la reducción de la urgencia de fumar o consumir tabaco, los métodos de fabricación de la formulación líquida mencionada, el uso de la formulación líquida mencionada para obtener la captación transdérmica de la nicotina a través de la piel del sujeto y el uso de nicotina para la producción de una formulación líquida para el tratamiento de un trastorno seleccionado del grupo consistente de la dependencia al tabaco o la nicotina, enfermedad de Alzheimer, enfermedad de Crohn, enfermedad de Parkinson, síndrome de Tourette y colitis ulcerosa, y para el tratamiento de control de peso después de dejar el hábito de fumar.
MX2009012486A 2007-05-16 2008-04-21 Una formulacion liquida para administrar nicotina. MX2009012486A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0701179 2007-05-16
PCT/SE2008/000279 WO2008140373A1 (en) 2007-05-16 2008-04-21 A liquid formulation for administering nicotine

Publications (1)

Publication Number Publication Date
MX2009012486A true MX2009012486A (es) 2009-12-02

Family

ID=40002445

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012486A MX2009012486A (es) 2007-05-16 2008-04-21 Una formulacion liquida para administrar nicotina.

Country Status (14)

Country Link
US (1) US20080287507A1 (es)
EP (1) EP2152227A4 (es)
JP (1) JP2010526877A (es)
KR (1) KR20100022049A (es)
CN (1) CN101686922A (es)
AR (1) AR066586A1 (es)
AU (1) AU2008251097B2 (es)
BR (1) BRPI0811858A2 (es)
CA (1) CA2685460A1 (es)
MX (1) MX2009012486A (es)
NZ (1) NZ580730A (es)
RU (1) RU2457822C2 (es)
WO (1) WO2008140373A1 (es)
ZA (1) ZA200908962B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071420A1 (es) 2008-05-01 2010-06-16 Smithkline Beecham Corp Composicion de pastilla para chupar oral que comprende un principio activo de nicotina y procedimiento para fabricarla
WO2011140315A2 (en) * 2010-05-05 2011-11-10 Northwestern University Method of reducing proteins misfolding and/or aggregation
CN103751060B (zh) * 2014-01-21 2016-03-30 江苏中烟工业有限责任公司 一种滋润保湿型烟草凝胶剂组合物及其制备方法
IT201800005821A1 (it) * 2018-05-29 2019-11-29 Miscela con nicotina
CN113208157B (zh) * 2021-05-07 2022-11-04 云南中烟工业有限责任公司 一种基于内消旋酒石酸烟碱盐胶凝剂的载香超分子凝胶
CN113367375B (zh) * 2021-05-12 2022-11-04 云南中烟工业有限责任公司 一种基于等酸碱比外消旋扁桃酸尼古丁盐胶凝剂的载香超分子凝胶
CN113880802A (zh) * 2021-11-09 2022-01-04 深圳萨特瓦生物科技有限公司 酒石酸-尼古丁盐及其制备方法与应用、无水酒石酸晶体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5016652A (en) * 1985-04-25 1991-05-21 The Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
GB8615676D0 (en) * 1986-06-26 1986-07-30 Stoppers Co Ltd Nicotine containing lozenge
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
ATE246909T1 (de) * 1994-03-07 2003-08-15 Theratech Inc Medikament enthaltende, adhesive, zusammenbaubare,transdermale abgabevorrichtung
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
SE9703458D0 (sv) * 1997-09-25 1997-09-25 Pharmacia & Upjohn Ab Nicotine compositions and methods of formulation thereof
US6479076B2 (en) * 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
FR2821270B1 (fr) * 2001-02-26 2003-06-13 Columbus Utilisation de nicotine libre pour la fabrication d'une composition anti-cellulitique
RU2189245C1 (ru) * 2001-10-01 2002-09-20 Закрытое акционерное общество "Косметический центр "ЛАКРИМА" Очищающий косметический гель
US7105173B1 (en) * 2002-03-21 2006-09-12 Rolling Kenneth J Nicotine replacement applique
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
GB0317868D0 (en) * 2003-07-30 2003-09-03 Disperse Ltd Biliquid foams with a high alcohol content and products formulated therefrom
RU2334507C2 (ru) * 2004-03-19 2008-09-27 Макнейл Аб Средство для чрескожного введения никотина

Also Published As

Publication number Publication date
KR20100022049A (ko) 2010-02-26
CA2685460A1 (en) 2008-11-20
EP2152227A4 (en) 2012-11-07
BRPI0811858A2 (pt) 2014-11-18
ZA200908962B (en) 2011-02-23
NZ580730A (en) 2013-04-26
EP2152227A1 (en) 2010-02-17
AU2008251097B2 (en) 2013-06-27
AU2008251097A1 (en) 2008-11-20
US20080287507A1 (en) 2008-11-20
AR066586A1 (es) 2009-09-02
WO2008140373A1 (en) 2008-11-20
RU2457822C2 (ru) 2012-08-10
RU2009146578A (ru) 2011-06-27
CN101686922A (zh) 2010-03-31
JP2010526877A (ja) 2010-08-05

Similar Documents

Publication Publication Date Title
MX2009012485A (es) Formulacion oral de nicotina amortiguada con aminoacidos.
MX2009012486A (es) Una formulacion liquida para administrar nicotina.
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
MY188825A (en) High-concentration monoclonal antibody formulations
NZ604029A (en) Methods of treating bladder cancer
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
NZ630367A (en) Methods of treatment of pediatric solid tumor
WO2011064402A3 (fr) Extrait de graines d'acacia macrostachya et compositions le comprenant
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2009009132A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naltrexona.
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
MX2010009270A (es) Compuestos y metodos para la prevencion o tratamiento de reestenosis.
SG10201807789WA (en) Vaginal composition and use thereof
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX360409B (es) Terapia de combinacion de dosis fija para la enfermedad de parkinson.
TW200724150A (en) Plant extracts for treating skin disorders and enhancing healing of wounds for diabetics patients
MX2009009134A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y nalmefeno.
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
JP2011184462A5 (es)
MX2015016750A (es) Composicion inmunogenica para uso en terapia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal